Immunotherapy as a Second-Line or Later Treatment Modality for Advanced Non-Small Cell Lung Cancer:
Document Type
Article
Publication Date
8-2020
Keywords
fsc2022
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85% of these cases. Surgical resection is the most common conventional treatment of lung cancer. For patients with advanced NSCLC, platinum-based chemotherapy remains the cornerstone of treatment. Although platinum-based chemotherapy demonstrated improved outcomes, the need for the second-line/later therapies is evident. A review was conducted to assess the safety and efficacy of immunotherapies as the second-line/later therapy of advanced NSCLC. Clinical trial data was collected via PubMed and Clinicaltrials.gov. Recent studies were selected based on prespecified inclusion/exclusion criteria. Data on the safety and efficacy of the immunotherapy was subsequently compiled from relevant trials. Monoclonal antibodies targeting PD-1/PD-L1 showed the most promising results as the second-line/later treatment modalities. Immunizations did not produce as robust of an immune response in participants; however, they warrant further research to determine their place in therapy.
DOI
10.1016/j.critrevonc.2020.103009
Publication Information
Chablani, Lipika and Geraci, Emily (2020). "Immunotherapy as a Second-Line or Later Treatment Modality for Advanced Non-Small Cell Lung Cancer:." Critical Reviews in Oncology/Hematology 152.103009.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.
